# Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

> **NCT02118285** · PHASE1 · COMPLETED · sponsor: **Masonic Cancer Center, University of Minnesota** · enrollment: 2 (actual)

## Conditions studied

- Ovarian Cancer
- Fallopian Tube Carcinoma
- Primary Peritoneal Carcinoma

## Interventions

- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide
- **BIOLOGICAL:** NK cells
- **BIOLOGICAL:** IL-2
- **DRUG:** INCB024360

## Key facts

- **NCT ID:** NCT02118285
- **Lead sponsor:** Masonic Cancer Center, University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07-28
- **Primary completion:** 2015-11-12
- **Final completion:** 2015-11-12
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2017-12-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02118285

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02118285, "Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02118285. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*